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ABSTRACT
Human (h)PTIP plays important but poorly under-
stood roles in cellular responses to DNA damage.
hPTIP interacts with 53BP1 tumour suppressor but
only when 53BP1 is phosphorylated by ATM after
DNA damage although the mechanism(s) and
significance of the interaction of these two proteins
are unclear. Here, we pinpoint a single ATM-
phosphorylated residue in 53BP1—Ser25—that is
required for binding of 53BP1 to hPTIP. Binding of
phospho-Ser25 to hPTIP in vitro and in vivo requires
two closely apposed pairs of BRCT domains at
the C-terminus of hPTIP and neither pair alone can
bind to phospho-Ser25, even though one of these
BRCT pairs in isolation can bind to other ATM-
phosphorylated epitopes. Mutations in 53BP1 and
in hPTIP that prevent the interaction of the two
proteins, render cells hypersensitive to DNA
damage and weaken ATM signalling. The C-terminal
BRCT domains of hPTIP are also required for stable
retention of hPTIP at sites of DNA damage but
this appears to be independent of binding to 53BP1.
Thus, the BRCT domains of hPTIP play important
roles in the cellular response to DNA damage.
INTRODUCTION
PTIP (Pax2 transactivation domain-interacting protein)
is a key regulator of cellular responses to DNA damage
that is vitally important for cell and organism function.
It was originally identified in mice in a two-hybrid screen
with the Pax2 transcription factor that regulates embryo-
nic development (1). PTIP null embryos do not recapitu-
late the phenotype of mice lacking Pax2, but instead show
very high levels of DNA damage and embryos die
at day E8.5 because the DNA damage sustained in
S-phase causes a mitotic block (2). These observations
suggested that PTIP plays an important role in regulating
genome stability.
Human (h)PTIP is required for survival of cells exposed
to ionizing radiation (IR) (2,3). hPTIP binds to sites
of DNA damage (3,4) and appears to function as an
‘adaptor’ protein in that it is required for IR-induced
phosphorylation of a subset of targets of the ATM
(ataxia telangiectasia-mutated) protein kinase (3).
ATM is a key regulator of cellular responses to double-
stand breaks (DSBs). Binding of ATM to sites of DNA
damage appears to stimulate ATM kinase activity (5),
leading to phosphorylation of target proteins at Ser–Gln
or Thr–Gln (S/T–Q) motifs (5–8). For example, ATM,
and the related kinase ATR, phosphorylate Ser129
of the core histone variant H2AX at sites of DNA
damage (9–11), and phospho-H2AX in turn acts as a
platform for the recruitment of proteins that are needed to
signal and repair DNA damage. The MDC1 protein,
for example, has a single pair of BRCT domains that
bind to phospho-Ser129 of H2AX, thereby recruiting
MDC1 and associated proteins to sites of DNA damage
(12). BRCT domains, mostly found in pairs, are
small modules of 100 amino acids (13) that mediate
protein–protein interactions. In some cases these
domains recognize phosphorylated epitopes on target
proteins (4,14).
hPTIP has a pair of BRCT domains at the N-terminus,
and another two pairs at the C-terminus (Figure 2A).
The most extreme C-terminal pair alone was shown
in vitro to bind to a library of phospho-peptides based
on the S/T-Q consensus sequence for phosphorylation
by ATM. The optimal sequence bound by this pair of
BRCT domains in vitro was found to be pS/T-Q-V-F (4).
hPTIP was shown to interact with 53BP1 after exposure
of cells to IR (3,4). 53BP1 is also an ‘adaptor’ protein
for ATM (15,16) and mice lacking 53BP1 are tumour
prone and are hypersensitive to IR (17–19). It was recently
shown that 53BP1 is down-regulated in transition from
pre-cancerous stage to carcinomas (20), and loss of a
single 53BP1 allele in mice causes genome instability
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and lymphoma (18). Cells lacking 53BP1 show mild cell
cycle checkpoint defects (16,17,21) and a pronounced
defect in the repair of a subset of DNA breaks by non-
homologous end joining (NHEJ) (22–24).
Intriguingly, the interaction of hPTIP and 53BP1 after
DNA damage requires ATM-dependent phosphorylation
of 53BP1 (3,4). Translocation of these proteins to sites
of DNA damage does not require ATM, however, and is
therefore independent of their physical association (3).
Although it was implied that binding of a phosphorylated
residue in 53BP1 that lies in the pS/T-Q-V-F motif, to the
most C-terminal BRCT domain pair in hPTIP explained
how these proteins interacted (4), this was not tested.
Thus, the mechanism(s) of interaction of hPTIP and
53BP1 or the significance of their interaction for the DNA
damage response is not yet known. In this study, we
address these questions.
MATERIALS AND METHODS
Cell lines and treatments
HEK 293 and U2OS cells were grown in DMEM (Gibco
BRL) supplemented with 10% fetal bovine serum (FBS,
HyClone) and penicillin/streptomycin. Cells were kept at
378C in a 5% CO2 atmosphere. Co-immunoprecipitation
of FLAG-hPTIP and HA-53BP1 proteins, SDS–PAGE
and western blot analysis were carried out as described
previously (3).
Antibodies and peptides
The primary antibodies used in this study were: anti-HA
(12CA5; Roche), anti-FLAG (M2; Sigma), anti-53BP1,
anti-phospho Ser1524 BRCA1 (Bethyl Laboratories),
anti-phospho Thr68 Chk2, anti-Chk2 (Cell Signaling
Technologies) and anti-BRCA1 (Oncogene Research
Products). Antibodies against hPTIP were described
previously (3). All peptides were synthesized by
Dr Graham Bloomberg, University of Bristol.
Plasmids, transfections, small interfering (si)RNA and
mutagenesis
Full-length 53BP1 was amplified from plasmid pCMH6K-
53BP1 (24) with an N-terminal HA tag, sub-cloned
into pCR2.1 and cloned into the KpnI and SalI sites
of pCMV5. To create the 53BP1 phospho-site mutants
shown in Figure 1, up to five mutations in 53BP1
at a time were introduced into 53BP1 using the
QuikChange Multi-Site mutagenesis kit (Stratagene) and
PCR reactions were spiked with Pfu Ultra DNA
polymerase (Stratagene). All plasmids were checked care-
fully by sequencing the entire insert forwards and
backwards.
Plasmids expressing hPTIP were described previously
(3). pCMV5-based plasmids were transfected into
HEK293 cells using calcium phosphate. In the siRNA/
rescue experiments, 53BP1 siRNA duplexes that recognize
nucleotides 84–104 in human 53BP1 (AAGCCA
GTTCTAGAGGATGA), or scrambled (SCR) duplexes
(100 nM) were co-transfected into cells with 53BP1 siMUT
plasmids (0.5 mg) in which 53BP1 bore a mutation at
nucleotide T93 that did not affect the coding sequence
but made 53BP1 refractory to silencing by siRNA.
The calcium phosphate method of transfection of
HEK293 cells was used for RNA interference and rescue
because this allowed transfection efficiencies of 490%
(data not shown). hPTIP depletion by siRNA duplexes
was described previously (3).
Protein expression and peptide pulldowns
The hPTIP BRCT domains were amplified from pCMV5-
hPTIP (3) and cloned into the BamHI site of pGEX6P3.
Proteins expression in Escherichia coli BL21 (DE3)-RIL
cells (Stratagene) was induced by addition of IPTG
at 10 mM, when cells were at OD600 0.6, at 168C for
16 h. Cells were lysed in 50mM Tris/HCl, pH 7.4
containing 1% (w/v) Triton X-100, 150mM NaCl, 1mM
EGTA, 1mM EDTA, 0.1% (v/v) 2-mercaptoethanol,
1mM benzamidine and 0.2mM phenyl methyl sulpho-
nate. After sonication of cells and centrifugation to
remove cell debris, proteins were purified on glutathione-
sepharose (AP Biotech) and eluted with a gradient of
reduced glutathione (Sigma). Proteins were dialysed free
of glutathione and stored frozen at 808C.
In each peptide pulldown, 3 mg of each peptide
[Non(P), biotin-DTPCLIIEDSQPEQVLEDD; Ser25(P),
biotin-DTPCLIIEDpSQPESQVLEDD; Ser29(P), biotin-
DTPCLIIEDSQPEpSQVLEDD; Ser25(P)/Ser29(P),
biotin-DTPCLIIEDpSQPEpSQVLEDD; Rad53(P),
biotin-MENIpTQPpTQQSTQAT; pS—phosphoserine,
pT—phosphothreonine] immobilized on 10 ml of
streptavidin-Dynabeads (Invitrogen) was incubated with
10 mg of recombinant protein in 50mM Tris/HCl, pH 7.4,
0.15M NaCl and 0.1% 2-mercaptoethanol for 60min
at room temperature. Beads were washed three times in
incubation buffer before bound proteins were eluted with
boiling LDS sample buffer and subjected to SDS–PAGE
on 4–12% Bis–Tris gels and Coomassie staining.
BiaCore analysis
Binding was analysed in a BiaCore 3000 system. The
relevant biotinylated peptides were bound to an SA sensor
chip (GE Healthcare). The indicated concentrations
of bacterially expressed wild-type and mutant forms
of GST–hPTIP (590–1069) (BRCT pairs C1+C2) in
HBS-EP [HEPES-buffered saline with EDTA and poly-
sorbate 20; 10mM HEPES, pH 7.4, 0.15M NaCl, 3mM
EDTA and 0.005% (v/v) polysorbate 20], were injected
over the immobilized peptides at a flow rate of 90 ml/min.
Interactions between each peptide and GST–hPTIP pair
C1+C2 (amino acids 590–1069) were analysed and
steady-state binding was determined at each concentra-
tion. Dissociation of GST–hPTIP pair C1+C2
forms from each peptide was monitored over 90 s.
Regeneration of the sensor chip surface between each
injection was performed with three consecutive 5 ml
injections of a solution containing 50mM NaOH
and 1M NaCl.
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RESULTS
Phosphorylation of 53BP1 at Ser25 is required
for its interaction with hPTIP
We previously reported that hPTIP interacts with 53BP1
only after DNA damage and that this requires
phosphorylation of 53BP1 by ATM. 53BP1 has a total
of 32 ATM consensus motifs (S/T-Q) (Figure 1A). The
Ser/Thr residues each of these motifs was mutated to
alanine and the resulting mutants were transfected
into HEK293 cells and tested for interaction with
co-transfected with FLAG-hPTIP. Mutation of the
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Figure 1. Identification of Ser25 of 53BP1 as the ATM-phosphorylated residue required for interaction with hPTIP after IR. (A) Schematic diagram
of full-length 53BP1. Asterisks represent S/T-Q motifs. The TUDOR domains and BRCT domains of 53BP1 are shown in green and blue,
respectively. In MUT-C10, the serine or threonine residue in each of the 10 most C-terminal S/T-Q motifs were mutated to alanine. In MUT-N17,
the 17 S/T-Q motifs immediately upstream of those in MUT-C10 were mutated. In MUT-N20, a further three S/T-Q motifs were mutated in addition
to those in MUT-N17. (B–D) HEK293 cells were co-transfected with FLAG-hPTIP and full-length HA-53BP1 bearing the indicated mutations. Cells
were exposed to IR (0Gy or 20Gy) and after cell lysis anti-FLAG immunoprecipitates were subjected to SDS–PAGE and western blotting with the
indicated antibodies. The lowest panel in each case shows HA-53BP1 levels in cell extracts. (E) HEK293 cells were pre-incubated with DMSO vehicle
or with 10 mM KU55933 or 10 mM NU7441 for 1 h before exposure to IR (10Gy) and then allowed to recover for the times indicated. Cells were
lysed in LDS sample and extracts subjected to SDS–PAGE followed by western blot analysis with the indicated antibody. (F) HEK293 cells grown
on 13-mm-diameter glass coverslips were transfected with full-length HA-53BP1: wild-type (WT) or the Ser25Ala mutant and then treated with 0 or
10Gy IR and left to recover at 378C for 45min before fixation and permeabilization as described previously (3). Cells were washed and blocked
before incubation with anti-HA (to detect transfected 53BP1).
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10 most C-terminal S/T-Q motifs in 53BP1 (termed
MUT-C10; Figure 1A) or mutation of a combination of
17 S/T-Q motifs upstream of the MUT-C10 mutations
(termed MUT-N17; Figure 1A) did not affect its interac-
tion with hPTIP after exposure of cells to IR (Figure 1B).
However, mutation of an additional three residues Ser25,
Ser29 and Ser105 (termed MUT-N20), abolished
the IR-inducible interaction of 53BP1 with hPTIP
(Figure 1B). Whereas mutation of Ser29, Ser105, Ser6 or
Ser13, singly had no effect, mutation of Ser25 of 53BP1
abolished the IR-induced interaction of 53BP1 and hPTIP
(Figure 1C and D). Thus, Ser25 in 53BP1 is essential for
the interaction of 53BP1 with hPTIP. It was reported
previously that 53BP1 is phosphorylated at Ser25 by ATM
(21). Consistent with this, we observed that Ser25 is
phosphorylated after exposure of HEK 293 cells to IR,
but not in cells pre-incubated with the ATM-specific
inhibitor KU55933 (25) (Figure 1E). Pre-incubation
of cells with NU7441 (26), a specific inhibitor of
DNA-dependent protein kinase (Figure 1E), or ablation
of ATR expression (27) (data not shown), did not affect
IR-induced phosphorylation of 53BP1 Ser25. The 53BP1
Ser25Ala mutant was retained at sites of DNA damage in
a manner indistinguishable from the wild-type protein (21)
(Figure 1F; data not shown). Therefore, the involvement
of Ser25 phosphorylation in promoting the interaction
of 53BP1 and hPTIP is independent of translocation of
53BP1 to sites of DNA damage. This is consistent with
previous reports that ATM is not required for formation
of IR-induced nuclear foci by 53BP1 or hPTIP (3,28).
The data in this section demonstrate that Ser25 that is
phosphorylated by ATM is essential for the interaction of
53BP1 with hPTIP after DNA damage and that this is
independent of 53BP1 translocation to IR-induced foci.
Two pairs of hPTIP BRCT domains are required for
binding to 53BP1 phospho-Ser25 in vitro and in vivo
We tested if phosphorylated Ser25 of 53BP1 could bind
directly to hPTIP. Two peptides corresponding to the
sequence around Ser25, in which Ser25 is phosphorylated
or not, were synthesized with a biotin moiety at the
N-terminal end. As a test for specificity, a peptide in which
nearby Ser29 is phosphorylated, and the Ser25/Ser29
diphospho-peptide, were also synthesized. Peptides were
immobilized on streptavidin-coated magnetic beads and
incubated with cell extracts. As shown in Figure 2B,
endogenous hPTIP was retrieved by the phospho-Ser25
peptide and phospho-Ser25/phospho-Ser29 peptide but
not by the unphosphorylated peptide or the phospho-
Ser29 peptide or by an unrelated diphospho-peptide from
yeast Rad53. Similar results were obtained with full-length
FLAG-hPTIP transfected into cells, and with a trans-
fected fragment of hPTIP (amino acids 590–1069)
(Figure 2B), corresponding to the two C-terminal pairs
of BRCT domains (pair C1+pair C2; Figure 2A), that we
previously showed were necessary and sufficient for hPTIP
to interact with 53BP1 after DNA damage in cells (3).
These data demonstrate that hPTIP interacts with
phosphorylated Ser25 of 53BP1 and that this is required
for the inducible interaction of the two proteins.
We assumed that just one of the two C-terminal pairs
of hPTIP BRCT domains is responsible for binding
phospho-Ser25. To test which of the two pairs was
responsible, the two isolated pairs or both pairs together
were expressed in bacteria as GST fusion proteins. Neither
the first (pair C1) nor the second (pair C2) pair of BRCT
domains in isolation bound to the Ser25 phospho-peptide
whereas both domains together (pair C1+pair C2)
bound efficiently (Figure 2C). BiaCore analysis demon-
strated that the dissociation constant (Kd) for binding of
BRCT pair C1+pair C2 to the phospho-Ser25 peptide
was 526 nM, whereas the Kd for binding to the non-
phospho-peptide was 41000 mM, demonstrating a high
degree of phospho-specificity (Figure 3A; data not
shown). The Kd of 526 nM is in good agreement with
other physiological BRCT–phosphoepitope interactions;
the Kd for Ser129 of H2AX and the BRCA1 BRCT
domain pair was reported to be 2.2 mM (12). BiaCore
measurements showed no detectable binding of hPTIP
BRCT pairs C1 or C2 in isolation to the phospho-Ser25
peptide (Figure 3B).
The requirement for two BRCT domain pairs for
recognition of phospho-Ser25 was surprising because in all
reported cases of phospho-epitope recognition by BRCT
domains, a single pair is sufficient and also because it was
reported that the BRCT domain pair C2 of hPTIP alone
bound to a library of degenerate pS/T-Q phosphopep-
tides. The optimal peptide used in these experiments
by Yaffe and colleagues (4) was biotin-GAAYDI-pSQ-
VFPFAKKK. In agreement with these data, even though
hPTIP BRCT domain pair C2 did not bind to 53BP1
phospho-Ser25, it bound to this phospho-peptide (termed
‘S-Q-V-F peptide’) with a Kd of 273 nM (data not
shown), and not to the unphosphorylated version of this
peptide (Figure 2D). These data taken together suggest
that BRCT pair C1+C2 of hPTIP are capable two modes
of phospho-epitope recognition: one specific for pS-Q-V-F
peptides mediated solely by pair C2, and another mode
that is responsible for binding phospho-Ser25 that needs
both pair C1+pair C2.
To confirm the requirement for two separate pairs of
BRCT domains in hPTIP to bind phospho-53BP1, the
effect of mutation of conserved residues in these domains
was determined. Inspection of the amino acid sequence of
hPTIP revealed that BRCT domain pair C2 contains a
small conserved motif that in other proteins recognizes
phospho-peptides. MDC1 and BRCA1 each have a single
pair of BRCT domains that interact with phospho-
peptides (12,14). Structural analyses showed that
Arg1933 of MDC1 and Arg1699 of BRCA1 coordinate
phospho-Ser and are essential for phospho-peptide bind-
ing (12,29,30). Alignment of each of the two C-terminal
pairs of BRCT domains from hPTIP, individually,
with the BRCT domain pairs from MDC1 and BRCA1
revealed clear conservation of residues involved in
phospho-specific binding in the second pair, but not in
the first pair, of hPTIP C-terminal BRCT domains
(Figure S1). Arg910 in BRCT pair C2 of hPTIP appears
to be equivalent to Arg1699 of BRCA1 and Arg1933 of
MDC1 (Figure S1). BiaCore measurements showed that
whereas pair C1+C2 bound to the 53BP1 phospho-Ser25
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peptide with a Kd of 526 nM, mutation of Arg910
(R910Q) severely reduced binding of BRCT pair
C1+pair C2 of hPTIP to phospho-Ser25 of 53BP1 so
that the Kd was so high that it was difficult to determine
(Figure 4A). Almost all BRCT domains have a conserved
Trp on the a3 helix (13) that corresponds to Trp676 in
hPTIP BRCT pair C1 and Trp929 in pair C2 (Figure S1).
Mutation of either Trp676 (W676A) or Trp929
(W929A) to alanine severely reduced binding to Ser25
phospho-peptide and in each case the Kd was41000mM
(Figure 4A). As shown in Figure 4B, mutation of Trp676,
Arg910 or Trp929 abolished binding of hPTIP to 53BP1
in IR-treated cells in vivo. These data are consistent with
the requirement for two pairs of BRCT domains for
hPTIP to recognize phospho-Ser25 of 53BP1.
A previous report showed that hPTIP BRCT pair C2
alone fused to GST could retrieve phosphorylated 53BP1
from extracts of irradiated cells (4). However, the data
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Figure 2. Both C-terminal BRCT domains of hPTIP mediate binding to phospho-Ser25 of 53BP1. (A) Schematic diagram of hPTIP. BRCT domains
are shown as blue boxes. (B) Extracts from untransfected HEK 293 cells (top panel; 4mg of extract protein), or cells transfected with full-length
FLAG-hPTIP (middle panel; 100mg of extract protein) or with FLAG-hPTIP (590–1069; 100mg of extract protein) corresponding to the two
C-terminal BRCT domains of hPTIP (‘Pair C1+Pair C2’; bottom panel) were incubated with Dynabeads conjugated to the indicated peptides,
corresponding to the sequence around Ser25 and Ser29 of 53BP1. The peptides used were: Empty, no peptide; Non(P), biotin-
DTPCLIIEDSQPEQVLEDD; Ser25(P), biotin-DTPCLIIEDpSQPESQVLEDD; Ser29(P), biotin-DTPCLIIEDSQPEpSQVLEDD; Ser25(P)/
Ser29(P), biotin-DTPCLIIEDpSQPEpSQVLEDD; Rad53(P), biotin-MENIpTQPpTQQSTQAT. (pS, phosphoserine, pT, phosphothreonine). After
extensive washing, beads were subjected to SDS–PAGE and western blot analysis with the indicated antibodies. (C) Bacterially expressed GST-hPTIP
(590–1069) (BRCT pairs C1+C2), GST-hPTIP (590–800) (BRCT pair C1) and GST-hPTIP (862–1069) (BRCT pair C2) were incubated with
Dynabeads conjugated to the indicated peptides (Figure 2B). After extensive washing, beads were subjected to SDS–PAGE and gels were stained
with Coomassie brilliant blue. (D) Same as C. except that Non(P) refers to the peptide biotin-GAAYDI-SQ-VFPFAKKK while S-Q-V-F (P) refers
to the peptide biotin-GAAYDI-pSQ-VFPFAKKK (4). Rad53(P) is described in (B).
5316 Nucleic Acids Research, 2007, Vol. 35, No. 16
presented in this study indicate that two hPTIP BRCT
pairs are required to bind to phospho-53BP1, and this
discrepancy was investigated. Protein fragments corre-
sponding to the hPTIP BRCT domains were expressed
as GST fusions in bacteria, immobilized and incubated
with extracts of cells exposed, or not, to IR. As shown
in Figure 4C, BRCT Pairs C1+C2 of hPTIP retrieved
53BP1 from extracts of irradiated cells much more
efficiently than from un-irradiated cells. The isolated
BRCT pair C2 of BRCT domains also retrieved 53BP1
from extracts of irradiated cells but with much lower
efficiency than hPTIP BRCT pairs C1+C2 (Figure 4C),
showing that pair C1 is important. Retrieval of 53BP1
from extracts by GST-hPTIP (590–1069) was prevented
by mutation of the W676A mutation in pair C1
(Figure 4C). Therefore, BRCT pair C2 of hPTIP only
binds very weakly to phospho-53BP1 in cell extracts
compared with a combination of both C-terminal
pairs of hPTIP BRCT domains. These data are consis-
tent with our previous finding that both C-terminal
pairs of hPTIP BRCT domains are necessary and
sufficient to interact with 53BP1 in cells after DNA
damage in vivo (3).
The interaction of 53BP1 and hPTIP is not required
for recruitment of hPTIP to sites of DNA damage
We previously showed that both C-terminal pairs of
BRCT domains in hPTIP are necessary and sufficient for
the formation of nuclear foci by hPTIP after DNA
damage (3). Since both these domains in hPTIP are also
required for binding to phospho-Ser25 of 53BP1, we
investigated if binding of the C-terminal domains of
hPTIP is required for stable retention of hPTIP at sites of
DNA damage. U2OS cells were transiently transfected
with plasmids expressing wild-type FLAG-hPTIP and
hPTIP bearing the following mutations: Trp676Ala
(W676A), Arg910Gln (R910Q) or Trp929Ala (W929A).
As shown in Figure 5A, formation of foci by endogenous
53BP1 was normal in all irradiated cells: this was used as
an internal control for focus formation. Wild-type hPTIP
formed nuclear foci after exposure of cells to IR
(Figure 5A): almost all cells had 450 foci under these
conditions, whereas most cells had510 foci in untreated
cells (Figure 5B). In contrast, mutation of Trp676 or
Trp929 prevented focus formation by hPTIP (Figure 5A);
very few cells had450 foci after IR, and almost all cells
had510 (Figure 5B). Mutation of Arg910 had little effect
on the ability of hPTIP to form foci after IR and
this mutant was difficult to distinguish from wild-type
hPTIP in this regard (Figure 5A and B). However, all
three of these mutations—Trp676Ala, Trp929Ala and
Arg910Gln—prevent the association of hPTIP with
phospho-Ser25 of 53BP1 in vitro and in vivo (Figure 4B).
Therefore, the two C-terminal BRCT domains of hPTIP
are essential for binding to sites of DNA damage but it
appears that this is independent of binding to phosphory-
lated Ser25 of 53BP1. This is consistent with our previous
finding that ATM,which catalyses Ser25 phosphorylation,
is not required for hPTIP to form nuclear foci after DNA
damage (3).
The interaction of 53BP1 with hPTIP is required
for an intact DNA damage response
We next wished to test if the interaction of 53BP1 and
hPTIP has important responses to DNA damage and we
first tested the effects of mutation of Ser25 of 53BP1.
Transfection of HEK293 cells with a siRNA duplex to
silence 53BP1 (16), but not with a scrambled (SCR)
version of this duplex, caused a dramatic reduction in
53BP1 protein levels (Figure 6A). An assay to allow
expression of ectopic HA-tagged 53BP1was then estab-
lished to allow complementation analysis. This involved
making a mutation in (HA-tagged) 53BP1 cDNA on a
plasmid at a point (T93) in the target sequence recognized
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describes the binding of a ligand to a receptor that follows the law of
mass action. Bmax is the maximal binding and Kd is the concentration
of ligand required to reach half-maximal binding, whereas x and y
correspond to the protein concentration and the response units,
respectively. (B) Same as A., except that binding of hPTIP BRCT
domain pair C1, C2 and pair C1+pair C2 to the 53BP1 phospho-
Ser25 peptide was compared.
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by the siRNA duplex, to render HA-53BP1 refractory to
siRNA-mediated silencing. Conditions were established so
that HA-53BP1 or HA-53BP1 in which Ser25 was mutated
to Ala were expressed at close to endogenous levels,
judged by immunoblotting with anti-53BP1 antibodies
(Figure 6A). Immunoprecipitation with anti-HA antibody
fully depleted 53BP1 from extracts of cells co-transfected
with 53BP1 siRNA and HA-53BP1 (data not shown).
This showed that all of the 53BP1 expressed under these
conditions corresponded to exogenous 53BP1.
53BP1 is required for ATM-dependent phosphorylation
of BRCA1 and CHK2 at low doses of radiation (16,17,21).
Consistent with these reports, depletion of 53BP1 caused a
severe reduction in phosphorylation of Chk2 at Thr68 and
phosphorylation of BRCA1 at Ser1524 (Figure 6A).
Whereas wild-type 53BP1 could rescue IR-induced
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Figure 4. Effect of mutation of conserved residues in the hPTIP BRCT domains on binding to phospho-53BP1 (A) The binding of bacterially
expressed hPTIP-BRCT pair C1+C2 proteins: wild type, W676A, R910Q and W929A to the 53BP1 phospho-Ser25 peptide (biotin-
DTPCLIIEDpSQPESQVLEDD) was analysed using BiaCore as described in the Materials and Methods section and in the legend to Figure 3A.
The inset shows a Coomassie-stained gel of the GST fusion proteins used in this analysis. (B) HEK293 cells were co-transfected with full-length
HA-53BP1 and FLAG-hPTIP bearing the indicated mutations. Cells were exposed to IR (0Gy or 20Gy) and after cell lysis anti-FLAG
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a Coomassie-stained gel of the GST-fusions used in this experiment. NS, non-specific.
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phosphorylation of Chk2 and 53BP1, mutation of Ser25
to Ala prevented this. We next looked at the effect of
mutation of Ser25 on cellular resistance to IR. Depletion
of 53BP1 rendered cells hypersensitive to IR (Figure 6B),
consistent with previous reports (17,22). Treatment of
53BP1-depleted cells with 3Gy of IR caused an 90%
decrease in cell viability, in contrast with an almost 40%
decrease in viability in cells treated with a scrambled
(SCR) RNA duplex (Figure 6B). 53BP1 in which Ser25
was mutated to alanine was unable to rescue this defect
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Figure 5. Interaction of 53BP1 with hPTIP is not required for stable retention of hPTIP at sites of DNA damage. (A) U2OS cells grown on 13-mm-
diameter glass coverslips were transfected with full-length FLAG-hPTIP: wild-type (WT) or the W676A, R910Q or W929A mutants and then treated
with 0 or 15Gy IR and left to recover at 378C for 45min before fixation and permeabilization as described previously (3). Cells were washed and
blocked before incubation with anti-FLAG (to detect transfected hPTIP) or with anti-53BP1 (1mg/ml) for 60min at room temperature. After
washing in PBS-T, coverslips were incubated with secondary antibodies (2 mg/ml) conjugated to Alexa488 or Alexa 594 (Jackson Laboratories) for
60min. After thorough washing in PBS-T, coverslips were mounted on glass slides and images were acquired using an Olympus IX70 microscope.
(B) The number of PTIP foci formed before and after exposure of cells to IR, in (A), was quantitated by counting the number of foci observed with
anti-FLAG antibody in 200 transfected cells. The mean number of foci SD are presented.
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whereas wild-type 53BP1 restored cellular resistance to IR
(Figure 6B). These data show that Ser25 of 53BP1, that
mediates the inducible interaction of 53BP1 with hPTIP, is
required for 53BP1 to act as an adaptor protein for ATM
and for cellular resistance to DSBs.
Mutation of Arg910 in hPTIP BRCT pair C2 prevents
binding of hPTIP to phospho-Ser25 of 53BP1 in vitro and
prevents binding of hPTIP to 53BP1after DNA damage
in cells, but does not affect hPTIP focus formation.
This mutation is therefore useful for probing the
consequences of the interaction of hPTIP with 53BP1
phospho-Ser25. hPTIP-specific RNAi was carried out in
HEK293 cells and this, like depletion of 53BP1, resulted in
a dramatic reduction in the IR-induced phosphorylation
of Chk2 at Thr68 and of BRCA1 at Ser1524 (Figure 6C).
Whereas wild-type FLAG-hPTIP could fully rescue these
defects, the Arg910Gln (R910Q) mutant could not.
Therefore, Arg910 of hPTIP BRCT pair C2 is required
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Figure 6. The interaction of 53BP1 with hPTIP is required for an intact cellular response to DNA damage. (A) HEK293 cells were co-transfected
with siRNA to silence 53BP1 or a scrambled RNA duplex (SCR), and with various plasmids: pCMV5 (), pCMV5-HA-53BP1 carrying a silent
mutation (see Materials and Methods section) that renders HA-53BP1 refractory to silencing by siRNA (WT), or pCMV5-HA-53BP1 with the same
mutation but with Ser25 mutated to alanine (S25A). Cells were exposed to IR (3Gy) and allowed to recover for the indicated times before lysis.
Extracts were subjected to SDS–PAGE and western blotting with the indicated antibodies. (B) Same as (A) except that cells were seeded at different
dilutions, in triplicate in 10-cm culture dishes and irradiated with 0 or 3Gy IR. Before plating, the viability of the cells was assessed during counting
by a dye exclusion test with trypan blue. After 14 days, colonies were fixed with methanol, stained with crystal violet and were counted if they
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FLAG-hPTIP with Arg910 mutated to glutamine (R910Q).
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for an intact response to DNA damage. These data
strongly suggest that recognition of 53BP1 phospho-Ser25
by the C-terminal BRCT domains of hPTIP is important
for maintenance of genome stability.
DISCUSSION
The data presented above demonstrate that the two pairs
of C-terminal BRCT domains of hPTIP are capable of at
least two modes of phospho-epitope recognition and that
they control at least two important, but independent,
facets of hPTIP function: interaction with phosphorylated
53BP1 and translocation to sites of DNA damage.
At the outset of this study, it was known that hPTIP
interacts with 53BP1 after DNA damage in an ATM-
dependent manner (3,4) but the mechanisms or signifi-
cance of this interaction were unclear. In this study, we
showed that a single ATM-phosphorylated residue in
53BP1—Ser25—is required for interaction with hPTIP in
cells. Mutation of Ser25 did not grossly perturb 53BP1
function since the 53BP1 Ser25Ala mutant protein formed
foci after DNA damage in a manner indistinguishable
from the wild-type protein (31) (data not shown).
Phosphorylated Ser25 was shown to interact with the
two C-terminal pairs (Pair C1+C2) of hPTIP (Figure 2).
We found that, surprisingly, both of these BRCT pairs are
required to bind to the phospho-Ser25 peptide and neither
domain alone could bind to this peptide (Figure 2B).
Consistent with these data, mutations of conserved
residues in Pair C1 (Trp676) or in Pair C2 (Arg910 or
Trp929) severely reduced binding of hPTIP to phospho-
Ser25 in vitro. Furthermore, mutation of any of these
residues abolished the binding of hPTIP to 53BP1 after
DNA damage in vivo. This is the first reported example of
a requirement of two pairs of BRCT domains for binding
to a single phospho-epitope. It is not yet clear why two
BRCT pairs are required to recognize 53BP1 phospho-
Ser25, especially when in BRCA1 and MDC1 (and in
other BRCT-proteins), a single BRCT pair in each case is
sufficient for interacting with phospho-H2AX and
phospho-BACH1, respectively (12,14). We predict that
the small conserved basic patch containing Arg910 in
hPTIP pair C2 contacts the phospho-Ser25 of 53BP1 and
that pair C1 makes contact with residues nearby, possibly
helping to determine the specificity of the interaction.
Solving the crystal structure of hPTIP BRCT domain
pairs C1+C2 in complex with the 53BP1 phospho-Ser25
peptide should provide valuable insight into the detailed
mechanism of this interaction.
The requirement for two pairs of BRCT domains for
hPTIP to recognize a single phospsho-epitope—Ser25 of
53BP1—is somewhat surprising since isolated BRCT
domain pair C2 of hPTIP was shown previously, in
peptide selection experiments, to interact with synthetic
phospho-peptides that lie in an pS/T-Q-V-F motif. Ser25
does not lie in this type of motif but there are two serine
residues in 53BP1—Ser29 and Ser105—that do conform
to the pS/T-Q-V-F motif, are not required for 53BP1to
bind hPTIP after DNA damage (Figure 1C). The
observation that hPTIP BRCT pairs C1+C2 recognize
a phospho-peptide different from the pS/T-Q-V-F pep-
tides bound by pair C2 in isolation suggests that there are
two modes of phospho-epitope recognition resident in
pairs C1+C2. Again, it would be interesting to compare
the crystal structure of hPTIP BRCT pairs C1+C2 in
complex with the two types of phospho-peptide to
ascertain whether different modes of interaction are at
play. It would be interesting to know if two types of
phosphopeptide bind in a mutually exclusive manner or if
they can bind to hPTIP simultaneously.
We showed previously that both BRCT pairs C1 and C2
are required for translocation of hPTIP to sites of DNA
damage. In this study, we showed that mutation of Trp676
in hPTIP BRCT pair C1 abolished formation of IR-
induced nuclear foci by hPTIP, as did mutation of Trp929
in pair C2 (Figure 5). However, the R910Q mutation that
also abolished binding of hPTIP to phospho-Ser25 and to
53BP1 in cells, did not affect formation of nuclear foci by
hPTIP after IR. Therefore, both C-terminal pairs of
BRCT domains in hPTIP appear to be essential for
binding of sites of DNA damage but this appears to be
independent of their ability to bind phospho-Ser25 of
53BP1. This is consistent with previous reports that ATM,
the Ser25 kinase, is not required for binding of hPTIP or
53BP1 to sites of DNA damage (3,28). At present, the
molecular mechanisms governing translocation of hPTIP
are not clear and this will be interesting to investigate.
Whatever the case, it is clear both C-terminal BRCT
domains of hPTIP are required.
Mutation of 53BP1 Ser25, that abolished interaction
with hPTIP, and mutation of Arg910 of hPTIP that
prevents interaction with phospho-Ser25, prevented phos-
phorylation of BRCA1 and Chk2 by ATM. Thus, 53BP1
must interact with hPTIP to exercise its role as adaptor
and to protect cells against DSBs. At present, it is not
clear how 53BP1 or hPTIP functions to assist ATM
phosphorylation but may involve recruitment of ATM
substrates to sites of DNA damage. Mutation of Ser25
also caused cells to become hypersensitive to IR, probably
indicative of a DNA repair defect, since 53BP1 are
defective in NHEJ of a subset of DSBs in cells (22). It
would be interesting to know if mutation of Ser25 in mice
recapitulates the same spectrum of tumours seen in 53BP1
null mice, and if mutation of Ser25 affects immunoglobu-
lin class switching. Neither 53BP1 nor hPTIP appear to
have catalytic activity and probably act as ‘scaffolding’
proteins to recruit and direct ‘effector’ polypeptides to
sites of DNA damage. Ultimately it will be vital to identify
the effector molecules that hPTIP and 53BP1 bring to sites
of DNA damage that facilitate DNA repair and that
enable phosphorylation of ATM targets.
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